A European Evergreen Investment Firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients. The firm is actively screening new investment opportunities and is open to reviewing opportunities from around the globe.

The firm seeks to invest in early-late stage biotech therapeutics, diagnostics, medical devices, and healthcare IT. Currently, the firm is highly interested in Gene and Cell therapies and patient stratification. Technologies/products that target orphan diseases or small patient populations are also of interest. The firm only selects truly revolutionary technologies and has no interest in incremental improvements to efficacy/safety.

The firm seeks to be a long term investor and does not look to exit or IPO their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

The firm is looking from companies with experienced management teams and will seek a board seat on a case by case basis when it is appropriate to do so. The firm is generally more comfortable with co-investing in early stage opportunities although they are not completely opposed to leading a round if the right opportunity were to present itself.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm is also willing to consider medical devices targeting these indication.

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A UK based venture capital firm is looking to invests in early-stage, high-growth life science and health technology companies. The firm (2013 vintage year) primarily provides Series A financing in the range of £2-5M. The firm is actively seeking new investment opportunities in the UK and Europe.

The firm is currently seeking to invest in novel early stage biotech therapeutic and diagnostic, medical devices and pharmaceuticals. The firm is opportunistic in terms of subsectors and indications. The firm is also interested in other areas such as personalized medicine, healthcare IT and services. For therapeutics, the firm focuses on products in pre-clinical and early clinical and will consider orphan indications.

The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm that firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

The firm is currently interested in companies in the Medical Device, Healthcare IT and Healthcare Services Sectors. In the Medical Devices space the firm is currently looking for companies shipping technologies that advance minimally invasive procedures in the fields of cardiology, urology, oncology, gynecology, orthopedics, neurosurgery and general surgery. The firm also looks for high-potential devices that serve an aging population that is seeking to stay active longer. Another area of interest is companies that are developing diagnostic technologies for personalized medicine.

The firm is looking for companies with revenues of at least $1-$2 million and the firm’s ideal candidates have revenues in the range of $3-$15 million. The firm has stated that they will gladly speak with medical device companies that may be outside of their investment scope in order to build relationships for the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture capital fund of a large Russian conglomerate with additional representation in New York, Zurich, and the UK id exclusively focused on early stage life science companies. The fund can invest up to USD 5 million per company generally in seed and series A rounds. The firm is open to investing globally and is actively seeking new investment opportunities. 

The fund is primarily focused on early-stage therapeutics, diagnostics, and medical devices. However, the firm may consider health IT. For therapeutics, the firm is agnostic in terms of subsectors and indications however only looking for products in pre-clinical to early-clinical is. The firm is also agnostic in terms of subsector and indication for diagnostics and medical devices but again is only interested in the early stage.

The fund seeks a strong and entrepreneurial management team and seek a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global beauty and health company is looking to invest in in early and later stage opportunities which are strategically relevant to and complement the firm’s current product lines. The firm’s investment size is USD 2-5 million per company per round with reserved follow-on investments. The firm can invest globally and is actively seeking new investment opportunities.

In the Life Sciences, the firm seeks to invest in emerging companies that develops novel cosmetic therapeutics and related medical devices. The firm’s investment focuses include dermatology therapeutics targeting, acne, stretch marks, rosacea, psoriasis, anti-fungal, as well as post-surgical treatment such as wound healing and scars. Other areas of interest include technology enhancing topical ingredient delivery, novel formulation technologies, emerging biotechnologies such as stem cells, gene profiling for cosmetic indications are also of interest.

On a case by case basis the firm can act as lead investor or participate in a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com